Conditions: Prostate Cancer
Keywords: CRPC Prostate Cancer Bone metastasis Advanced Castration-Resistant Prostate Cancer (CRPC)
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 6
Healthy volunteers: no

Brief summary:
The main objective of this study is to evaluate the effects of PLX3397 on male subjects with CRPC.

Secondary objectives include evaluating the safety and tolerability of PLX3397 and the anti-tumor effects that PLX3397 has on the the subjects.

Detailed description:

Arms:
arm 1: Participants will take daily oral dose of PLX3397 for 28 day cycles. Participants will continue to take PLX3397 until disease progression or toxicity.

Interventions: intervention 1: PLX3397
Intervention descriptions: intervention 1: Capsules administered twice daily, continuous dosing. Subjects will take PLX3397 at 1000 mg/day.

Protocol document: